RSS-Feed abonnieren
DOI: 10.1055/a-2510-5592
Intravitreal Enzyme Replacement Therapy Slows Retinopathy in Late Infantile Ceroid Lipofuscinosis Type 2
Abstract
Ceroid lipofuscinosis type 2 (CLN2) is caused by biallelic pathogenic variants in the TPP1 gene, encoding lysosomal tripeptidyl peptidase 1 (TPP1). The classical late-infantile phenotype has an age of onset between 2 and 4 years and is characterized by psychomotor regression, myoclonus, ataxia, blindness, and shortened life expectancy. Vision loss occurs due to retinal degeneration, usually when severe neurological symptoms are already evident.
Intracerebroventricular enzyme replacement therapy (ICV-ERT) using recombinant human TPP1 (rhTPP-1) was shown to slow the neurological decline; however, it does not prevent loss of vision. Intravitreal rhTPP-1 (IVT-ERT) was described to halt retinal degeneration in a canine CLN2 model and a compassionate-use study in humans.
We report on the clinical and ophthalmological outcome in an early-treated patient homozygous for a pathogenic variant in TPP1 known to be associated with severe CLN2 retinopathy.
He was started on ICV-ERT at the age of 40 months and 4 weekly IVT-ERT in one eye at the age of 60 months. The other eye served as untreated control.
Baseline best corrected visual acuity (BCVA) was 0.5 with mild bull's eye maculopathy evident in both eyes. After 24 months of IVT-ERT, BCVA in the treated eye was 0.2 with bull's eye maculopathy sparing outer retinal layers, whereas the untreated eye had progressed to endstage retinopathy and BCVA <0.02. No intraocular side effects occurred.
Our results provide further evidence that IVT-ERT appears to be safe and markedly delays retinal degeneration preserving visual function and increasing the patient's quality of life, especially if started early.
Keywords
neuronal ceroid lipofuscinosis - ceroid lipofuscinosis type 2 - intracerebroventricular enzyme replacement therapy - retinopathy - intravitreal enzyme replacement therapy - cerliponase alfaPublikationsverlauf
Eingereicht: 21. Oktober 2024
Angenommen: 02. Dezember 2024
Accepted Manuscript online:
07. Januar 2025
Artikel online veröffentlicht:
21. Januar 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R. NCL diseases—clinical perspectives. Biochim Biophys Acta 2013; 1832 (11) 1801-1806
- 2 Steinfeld R, Heim P, von Gregory H. et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet 2002; 112 (04) 347-354
- 3 Schaefers J, van der Giessen LJ, Klees C. et al. Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa. Orphanet J Rare Dis 2021; 16 (01) 221
- 4 Nickel M, Simonati A, Jacoby D. et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health 2018; 2 (08) 582-590
- 5 Dozières-Puyravel B, Nasser H, Elmaleh-Bergès M. et al. Paediatric-onset neuronal ceroid lipofuscinosis: first symptoms and presentation at diagnosis. Dev Med Child Neurol 2020; 62 (04) 528-530
- 6 Kovacs KD, Patel S, Orlin A. et al. Symmetric age association of retinal degeneration in patients with CLN2-associated Batten disease. Ophthalmol Retina 2020; 4 (07) 728-736
- 7 Orlin A, Sondhi D, Witmer MT. et al. Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function. PLoS One 2013; 8 (08) e73128
- 8 Schulz A, Ajayi T, Specchio N. et al. CLN2 Study Group. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med 2018; 378 (20) 1898-1907
- 9 Schulz A, Specchio N, de Los Reyes E. et al. Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study. Lancet Neurol 2024; 23 (01) 60-70
- 10 Thompson DA, Handley SE, Henderson RH, Marmoy OR, Gissen P. An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy. Eye (Lond) 2021; 35 (09) 2438-2448
- 11 Dulz S, Schwering C, Wildner J. et al. Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease). Br J Ophthalmol 2023; 107 (10) 1478-1483
- 12 Whiting REH, Pearce JW, Vansteenkiste DP. et al. Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis. Exp Eye Res 2020; 197: 108130
- 13 Wawrzynski J, Martinez AR, Thompson DA. et al. First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy. Eye (Lond) 2024; 38 (06) 1176-1182
- 14 Rodriguez-Martinez AC, Wawrzynski J, Henderson RH. Intravitreal enzyme replacement for inherited retinal diseases. Curr Opin Ophthalmol 2024; 35 (03) 232-237
- 15 Rigaudière F, Nasser H, Pichard-Oumlil S. et al. Evolution of the retinal function by flash-ERG in one child suffering from neuronal ceroid lipofuscinosis CLN2 treated with cerliponase alpha: case report. Doc Ophthalmol 2021; 143 (01) 99-106